Betacellulin induces Slug-mediated down-regulation of E-cadherin and cell migration in ovarian cancer cells

Epithelial ovarian cancer is the leading cause of death among gynaecological cancers. Previous studies have demonstrated that epidermal growth factor receptor (EGFR) ligands can induce ovarian cancer cell invasion by down-regulating E-cadherin. Betacellulin is a unique member of the EGF family. It is overexpressed in a variety of cancers and is associated with reduced survival. However, the biological functions and clinical significance of betacellulin in ovarian cancer remain unknown. In the current study, we tested the hypothesis that betacellulin induces ovarian cancer cell migration by suppressing E-cadherin expression. Treatment of SKOV3 and OVCAR5 ovarian cancer cell lines with betacellulin down-regulated E-cadherin, but not N-cadherin. In addition, betacellulin treatment increased the expression of Snail and Slug, and these effects were completely blocked by pre-treatment with EGFR inhibitor AG1478. Interestingly, only knockdown of Slug reversed the down-regulation of E-cadherin by betacellulin. Betacellulin treatment induced the activation of both the MEK-ERK and PI3K-Akt signaling pathways, and it also significantly increased ovarian cancer cell migration. Importantly, the effects of betacellulin on E-cadherin, Slug and cell migration were attenuated by pre-treatment with either U0126 or LY294002. Our results suggest that betacellulin induces ovarian cancer migration and Slug-dependent E-cadherin down-regulation via EGFR-mediated MEK-ERK and PI3K-Akt signaling.

[1]  C. Muller,et al.  High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer , 2014, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[2]  M. Azodi,et al.  Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence , 2014, Cancer Prevention Research.

[3]  Qun Wang,et al.  Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells , 2014, Journal of Translational Medicine.

[4]  R. Kurman.  Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  N. Auersperg.  Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? , 2013, Gynecologic oncology.

[6]  P. Leung,et al.  HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. , 2013, Biochemical and biophysical research communications.

[7]  I. Paatero,et al.  CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. , 2013, Gynecologic oncology.

[8]  P. Leung,et al.  Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. , 2013, Cancer letters.

[9]  K. Shen,et al.  The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. , 2012, Cancer epidemiology.

[10]  J. Menéndez,et al.  Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. , 2012, International journal of oncology.

[11]  P. Leung,et al.  EGF-Induced EMT and Invasiveness in Serous Borderline Ovarian Tumor Cells: A Possible Step in the Transition to Low-Grade Serous Carcinoma Cells? , 2012, PloS one.

[12]  P. Leung,et al.  Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin , 2011, Oncogene.

[13]  Q. Sheng,et al.  The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer , 2011, British Journal of Cancer.

[14]  I. Brandslund,et al.  Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. , 2008, International journal of oncology.

[15]  K. Jang,et al.  Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. , 2006, Human pathology.

[16]  S. Eccles,et al.  Signaling pathways required for matrix metalloproteinase‐9 induction by betacellulin in head‐and‐neck squamous carcinoma cells , 2004, International journal of cancer.

[17]  M. Mifune,et al.  Signal transduction of betacellulin in growth and migration of vascular smooth muscle cells. , 2004, American journal of physiology. Cell physiology.

[18]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Cho,et al.  Betacellulin induces angiogenesis through activation of mitogen‐activated protein kinase and phosphatidylinositol 3’‐kinase in endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[21]  H. Modjtahedi,et al.  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. , 2000, Cancer research.

[22]  W. Gullick,et al.  Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 α, Neuregulin-1 β, and Betacellulin, in Normal Endometrium and Endometrial Cancer , 1999 .

[23]  T. Otonkoski,et al.  Growth Factor-Mediated Proliferation and Differentiation of Insulin-Producing INS-1 and RINm5F Cells: Identification of Betacellulin as a Novel β-Cell Mitogen. , 1998, Endocrinology.

[24]  H. Friess,et al.  Betacellulin, a member of the epidermal growth-factor family, is overexpressed in human pancreatic-cancer. , 1995, International journal of oncology.

[25]  S. Ramakrishnan,et al.  Differential expression of the cell‐cell adhesion molecule E‐cadherin in ascites and solid human ovarian tumor cells , 1994, International journal of cancer.

[26]  D. Hanahan,et al.  Betacellulin: a mitogen from pancreatic beta cell tumors. , 1993, Science.

[27]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[28]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[29]  M. Imamura,et al.  Auto-induction and growth stimulatory effect of betacellulin in human pancreatic cancer cells. , 2000, International Journal of Oncology.